ArticleDiabetes2026
α/β-Hydrolase Domain Containing 5 Supports Glucose-Stimulated Lipolysis and Insulin Secretion in Pancreatic β-Cells.
Article in Diabetes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
10 authors.
Funding
Abstract
Adipose triglyceride (TG) lipase (ATGL) is the rate-limiting enzyme of TG catabolism at the surface of lipid droplets (LDs). In pancreatic β-cells, lipolysis by ATGL increases with glucose and produces metabolites that support glucose-stimulated insulin secretion (GSIS). Upregulation of lipolysis by glucose is blunted in human islets affected by type 2 diabetes. However, how glucose regulates lipolysis in β-cells is unknown. We found that glucose recruits ATGL coactivator α/β-hydrolase domain containing 5 (ABHD5) to LDs in INS-1 cells and human β-cells. ABHD5 recruitment to LDs was reduced by inhibitors of cAMP-dependent protein kinase (PKA) or the expression of PKA-resistant mutant ABHD5, indicating that PKA phosphorylation contributes to ABHD5 recruitment to LDs. Importantly, ABHD5 was indispensable for glucose-stimulated lipolysis in INS-1 cells and human β-cells. ABHD5 knockdown increased LDs and TG content in INS-1 cells and human islets, indicating that ABHD5 is a critical regulator of ATGL activity in β-cells. Additionally, GSIS was impaired in ABHD5-downregulated INS-1 cells and human pseudoislets, which agrees with a role of ATGL in supporting GSIS in β-cells. Thus, ABHD5 plays an important role in conferring glucose responsiveness in lipolysis and supporting insulin secretion in β-cells. ARTICLE HIGHLIGHTS: Lipolysis is stimulated by glucose and supports glucose-stimulated insulin secretion in pancreatic β-cells. However, the mechanism by which glucose increases lipolysis in β-cells is unknown. We aimed to identify a glucose-responsive regulator of lipolysis in β-cells. Glucose promotes α/β-hydrolase domain containing 5 (ABHD5) recruitment to lipid droplets where lipolysis occurs, which is at least partially mediated by cAMP-dependent kinase A. ABHD5 is required for glucose-stimulated lipolysis and insulin secretion. ABHD5 is a potential target to restore glucose-stimulated lipolysis in β-cells affected by type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.